Status:
COMPLETED
Wellbutrin XL Effects on SSRIs Induced Changes
Lead Sponsor:
Indiana University School of Medicine
Conditions:
Depression
Side Effects
Eligibility:
All Genders
18-60 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to find out differences in activation of mood regulating areas of the brain in response to negative and positive pictures, before and after 6 weeks of additional Wellbutri...
Detailed Description
Hypotheses: Hypothesis 1.After wellbutrin XL addition for 6 weeks, SSRI treated subjects will show increased activation and connectivity of prefrontal cortex and limbic regions such as the amygdala o...
Eligibility Criteria
Inclusion
- Ages 18 - 60 years and able to give voluntary informed consent.
- Satisfy criteria for recent treatment with for Major Depressive Episode using DSM-IV episode recently treated with an adequate dose of an SSRI (sertraline, paroxetine, fluoxetine, citalopram, escitalopram) with 17-item Hamilton Depression Rating Scale (HDRS) score \< 18.
- Complaining of symptoms of apathy, lack of feeling or sexual dysfunction with AES score \< 10 and/or MADRAS item 8 (inability to feel \> 1) and/or CSFQ score \> 10
- Satisfy criteria to undergo an MRI scan based on MRI screening questionnaire. 5) Able to be managed as outpatients for initial assessment and during treatment as ascertained by the following - Symptoms not worsening by more than 10 points on the HDRS during the course of the study and not representing danger to self or others.
Exclusion
- Meeting DSM-IV criteria for bipolar disorder, schizophrenia, schizophreniform disorder, schizoaffective disorder, atypical psychosis, primary anxiety disorder, mental retardation, or organic mental (including organic mood) disorder.
- Use of neuroleptic in the past 1 year.
- History of seizure disorder
- History of eating disorders such as bulimia or anorexia nervosa
- History of lack of response or intolerance to bupropion.
- Use of mood stabilizers in the past 2 weeks.
- Use of benzodiazepines in the past 2 weeks.
- Acutely suicidal or homicidal or requiring inpatient treatment.
- Meeting DSM-IV criteria for other substance dependence, including alcohol within the 6 months, except caffeine or nicotine. The criteria will be evaluated by interview and urinary toxicology screening initially and on test days.
- Use of alcohol in the past 1 week.
- No serious medical or neurological illness as assessed by physical examination and laboratory examination including CBC and blood chemistry.
- Abnormal TSH values. If on synthroid should be on a stable dose for 3 months prior to the study with no changes during the study.
- Current pregnancy or breast-feeding.
- Metallic implants.
- Previously known positive HIV blood test (as latent central dysfunction may be present) as reported by the subject.
Key Trial Info
Start Date :
July 1 2004
Trial Type :
INTERVENTIONAL
End Date :
November 1 2007
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT00456820
Start Date
July 1 2004
End Date
November 1 2007
Last Update
October 16 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Indiana University Adult Psychiatry Clinic
Indianapolis, Indiana, United States, 46202